Methionine is an essential sulfur-containing amino acid that is the starting point of the methylation cycle and the transsulfuration pathway — the two most important biochemical pathways in human nutrition that involve sulfur. Methionine is converted to S-adenosylmethionine (SAM), the universal methyl donor for over 100 methyltransferases in the body; it is converted to homocysteine after donating its methyl group; and from homocysteine, the transsulfuration pathway branches in two directions — back toward methionine (via the folate-dependent remethylation pathway) or forward toward cysteine (via the cystathionine pathway). This methionine-centred network is the foundation of all sulfur metabolism in the body, and its dysfunction is implicated in some of the most common chronic diseases of modern civilisation, including cardiovascular disease, neurodegenerative disease, and cancer.
The Methionine Cycle
In the methionine cycle, methionine is activated by methionine adenosyltransferase (MAT) to form S-adenosylmethionine (SAM), which is the primary methyl donor for all methylation reactions in the body. SAM-dependent methylation reactions include the methylation of DNA (which regulates gene expression), the methylation of histones (which regulate chromatin structure and the epigenetic state of the cell), the methylation of RNA (which regulates protein synthesis and gene expression), the methylation of proteins (which regulates their activity), and the methylation of neurotransmitters (including the synthesis of adrenaline from noradrenaline, which requires SAM as the methyl donor). After donating its methyl group, SAM becomes S-adenosylhomocysteine (SAH), which is hydrolysed to homocysteine. Homocysteine is then either remethylated to methionine (by methionine synthase, MS, which requires B12 and folate as cofactors) or converted to cysteine via the transsulfuration pathway.
The clinical significance of the methionine cycle is underscored by the association between homocysteine and cardiovascular disease. Elevated homocysteine (hyperhomocysteinemia) is an independent risk factor for atherosclerotic cardiovascular disease, stroke, and venous thromboembolism. The mechanism by which homocysteine damages blood vessels involves endothelial dysfunction (by reducing nitric oxide production and increasing superoxide production), the promotion of LDL oxidation (by increasing oxidative stress in the vascular wall), the activation of the coagulation cascade (by increasing the expression of tissue factor and von Willebrand factor), and the stimulation of vascular smooth muscle cell proliferation. Each 5 micromol/L increase in fasting homocysteine is associated with approximately 20% increased risk of coronary heart disease and stroke.
The Transsulfuration Pathway and Taurine Synthesis
The transsulfuration pathway converts homocysteine to cysteine, and cysteine is then used for the synthesis of three of the most important sulfur-containing compounds in the body: glutathione (the primary intracellular antioxidant), taurine (the second most abundant amino acid in the body, with diverse functions in the heart, brain, and skeletal muscle), and coenzyme A (CoA, which is required for the function of the TCA cycle and for the metabolism of fatty acids). The first step of the transsulfuration pathway is catalysed by cystathionine beta-synthase (CBS), which requires vitamin B6 (as PLP) as a cofactor; the second step is catalysed by cystathionine gamma-lyase (CGL), which also requires PLP. The transsulfuration pathway is the primary source of cysteine for glutathione synthesis and is the pathway by which the body maintains its cysteine and glutathione status under conditions of dietary cysteine deficiency.
Methionine Restriction and Longevity
Methionine restriction (reducing dietary methionine intake by 40-60%) extends lifespan in every organism tested. The proposed mechanisms include reduced mTOR signalling, activation of the Nrf2 antioxidant response, enhanced autophagy, and reduced sulfur-containing amino acid derivatives that drive oxidative stress and inflammation. While severe methionine restriction is impractical for humans, the evidence suggests that moderating methionine intake (without causing deficiency) may be beneficial for healthy longevity — and that the typical Western diet, which is high in methionine (from animal proteins), may be in excess of the optimal amount for healthspan. The evidence for moderate methionine restriction in humans is still preliminary, but the consistency of the findings across all model organisms makes this one of the most promising longevity interventions awaiting human confirmation.
Practical Application
For general methylation and sulfur amino acid support, the evidence-based approach is to ensure adequate methionine intake from dietary protein while maintaining adequate folate, B12, and B6 status for the methylation and transsulfuration pathways. The RDA for methionine plus cysteine is approximately 1.1-1.3g daily for adults, and most people obtain adequate methionine from a varied diet. For people with elevated homocysteine, supplementation with folate (as 5-MTHF at 400-800mcg daily), vitamin B12 (as methylcobalamin at 500-1,000mcg daily), and vitamin B6 (as PLP at 10-25mg daily) is the evidence-based approach for lowering homocysteine. For comprehensive sulfur metabolism support, methionine pairs well with the B-complex vitamins, with trimethylglycine (for additional methyl groups), with NAC (for glutathione synthesis), and with the omega-3 fatty acids.
Leave a Reply